Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.

Theolytics’ ongoing US phase 1 OCTOPOD-IP trial of THEO-260 in ovarian cancer to be presented as a trial in progress at ASCO 2026

THEO-260 is an oncolytic immunotherapy designed to effectively target cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich tumours. The US trial (OCTOPOD-IP) is exploring the safety and tolerability of intraperitoneal delivery of THEO-260 in high-grade serous or endometroid ovarian cancer.

Theolytics announces first patient dosed in the OCTOPOD-IP Trial, a US phase 1 trial with THEO-260, a novel oncolytic immunotherapy targeting ovarian cancer

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).

Enara Bio presents first-in-class DARKFOX-Targeting bispecific T Cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential in solid tumour immunotherapy

ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumour-specific targets derived from the dark proteome.

Alethio Therapeutics unveils ATX‑011, a breakthrough, mutation‑agnostic antibody for treating essential thrombocythemia – a c.$2B market, and strengthens leadership to accelerate path to IND

Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. Alongside this, the Company announces the appointment of Steve R. Coats, PhD, a veteran biologics leader, as Chief Development Officer, to advance the ATX-011 programme towards IND submission, targeted for Q1 2027.

Bioarchitech secures strategic material license with the UK Health Security Agency (UKHSA) to support manufacturing and clinical development of BA-V151

Bioarchitech, Oxford, UK, an immuno-oncology therapeutics start-up company announces that it has secured a material license from the European Collection of Authenticated Cell Cultures (ECACC), UKHSA for a mammalian cell line to be developed as a scalable and high yield viral manufacturing platform and for the vector backbone of BA-V151, a preclinical stage candidate being developed as a treatment for metastatic cancers.

PepGen announces topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing phase 2 FREEDOM2 study demonstrating favourable safety, splicing and vHOT data

PGN-EDODM1 was generally well-tolerated, with all adverse events being mild or moderate, and no serious adverse events reported. The mean splicing correction observed with PGN-EDODM1 (n=6) was 7.3%, compared to 6.8% for the placebo (n=2). Excluding one outlier patient, the treatment group showed a mean splicing correction of 22.9% (n=5). Promising trends were seen in vHOT in the PGN-EDODM1 treated group. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027.

Enara Bio to unveil first-in-class DARKFOX-targeting bispecific T cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential for solid tumour immunotherapy

Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX®, a novel cancer-specific Dark Antigen discovered with Enara’s EDAPT® platform.

Let’s just get married – the story of an acquisition

"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.

Theolytics awarded €8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer

Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.

CyanoCapture and Persist AI announce strategic collaboration to build world's first robotic GMP facility for oral protein and peptide drugs

The pioneering partnership combines cyanobacteria-based oral delivery with AI-driven robotics to transform how life-saving biologics reach patients.

Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer

Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment reflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.

OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.

Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies

Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara’s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara’s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.

Certis Belchim and Moa sign strategic collaboration deal

Netherlands-based company becomes Moa's third major commercial partner in 18 months.

Nucleome Therapeutics nominates first preclinical development candidate

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.

Abbott to acquire Exact Sciences

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.

Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease

Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.

Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.

PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule

The Composition of Matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.

Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell

Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics.

Load More

Similar stories